Targeting glutaminase was explored as a method to suppress glutamine metabolism and cancer cell growth.1 Compared with the strategy to inhibit GLS, there is reason to believe that blocking cellular glutamine uptake by the combination of silencing ASCT2 with V-9302 could be more beneficial than targeting downstream glutaminase activity, which does not fully inhibit the function of extramitochondrial glutamine. Here, SLC1A5 is linked to cancer.